Hikma Pharmaceuticals (LON:HIK) Receives Buy Rating from Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report sent to investors on Thursday,Digital Look reports. They currently have a GBX 2,300 target price on the stock.

Other equities analysts have also issued reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. JPMorgan Chase & Co. cut their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research note on Friday, January 9th. Finally, Peel Hunt reissued a “buy” rating and set a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of GBX 2,326.

Hikma Pharmaceuticals Trading Down 1.7%

Hikma Pharmaceuticals stock opened at GBX 1,542 on Thursday. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a market cap of £3.41 billion, a PE ratio of 9.23, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The stock has a 50-day moving average of GBX 1,551.96 and a two-hundred day moving average of GBX 1,711.93. Hikma Pharmaceuticals has a one year low of GBX 1,482 and a one year high of GBX 2,360.

Insider Buying and Selling at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Said Darwazah bought 60,000 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Friday, November 7th. The stock was purchased at an average price of GBX 1,589 per share, with a total value of £953,400. Also, insider Victoria Hull bought 3,214 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were acquired at an average price of GBX 1,547 per share, with a total value of £49,720.58. In the last ninety days, insiders acquired 448,214 shares of company stock worth $712,497,058. Company insiders own 18.15% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.